Inhibited interleukin 35 expression and interleukin 35–induced regulatory T cells promote type II innate lymphoid cell response in allergic rhinitis

• DOI: 10.1016/j.anai.2020.08.005
• Publication Date: 2020-08-07T01:10:39Z
• Authors: Wenlong Liu; Qingxiang Zeng; Yanhui Wen; Yiquan Tang; Shengbao Yan; Yan Li; Lifeng Zhou; Renzhong Luo
• Keywords: Innate lymphoid cell; Interleukin 33

BackgroundInterleukin (IL)-35 and IL-35–producing regulatory T cells (iTr35) have been reported to inhibit TH2 response in allergic rhinitis (AR). However, its effects on type II innate lymphoid (ILC2) are not well characterized.ObjectiveTo investigate the effect of IL-35 ILC2 AR.MethodsA total 25 patients with AR 20 controls were recruited. The expression regulation receptor analyzed by real-time polymerase chain reaction. differentiation cytokine production was reaction enzyme-linked immunosorbent assay. In addition, iTr35 cocultured explore ILC2. mice models also established confirm role vivo.ResultsThe had decreased proportion increased cytokines compared controls. Notably, inhibited regulating IL-12Rβ2 gp130. promoted inducible costimulatory molecule ligand IL-35–treated presented frequency function nasal ILC2.ConclusionIL-35 responses directly or through mutual contact between AR, suggesting that may be used as a potential treatment target AR.